Oxford Biomedica plc reiterated earnings guidance for the year 2024. For the year, the company expected total Group revenues of between £126 million and £134 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
334.5 GBX | +1.83% | +1.06% | +52.05% |
May. 09 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
May. 09 | Molten Ventures wins UK MoD supply contract | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.05% | 418M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024